Virtual Library

Start Your Search

Zhihuang Hu



Author of

  • +

    P1.04 - Immuno-oncology (ID 164)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.04-20 - PD-L1 mRNA Derived from Tumor-Educated Platelets Predicts the Clinical Outcome of Immunotherapy in Non-Small Cell Lung Cancer (ID 2982)

      09:45 - 18:00  |  Author(s): Zhihuang Hu

      • Abstract

      Background

      Immunotherapy was promising treatment of advanced non-small cell lung cancer (NSCLC), but only a small part of patients could benefit from the immune checkpoint inhibitors (ICIs). Development of novel biomarkers was of great importance to improve the selection of patients and to avoid unnecessary toxicity.

      Method

      We collected data from advanced NSCLC patients who received immunotherapy alone or in combination with chemotherapy as first- or second-line treatment at a single institution. All the patients were wild type of EGFR/ALK and enrolled into clinical trials on ICIs, including nivolumab, pembrolizumab, atezolizumab, durvalumab, tremelimumab and camrelizumab. PD-L1 messenger RNA (mRNA) was detected from tumor-educated platelets before ICIs treatment. Meanwhile, tumoral PD-L1 expression was also determined by immunohistochemistry in archived tissue samples to explore its predictive value and association with TEPs- derived PD-L1 mRNA expression.

      Result

      Of 76 patients enrolled into this study, 68 patients (89.5%) received only immunotherapy and 23 patients (30.3%) responded to the treatment, and the median PFS was 3.81 months. There was no correlation between tumoral PD-L1 expression and TEPs-derived mRNA of PD-L1 by Pearson Correlation test (P=0.32). Based on the median of PD-L1 mRNA, 19 patients (44.4%) responded to immunotherapy in high PD-L1 group compared to 5 patients (13.9%) in low PD-L1 group (P<0.01). The median PFS were 2.76 months in low PD-L1 group, compared to 8.28 months in high PD-L1 group (P<0.001), respectively. For the 64 patients who received only immunotherapy, the PFS advantage was persistent in high PD-L1 group (2.76 vs 8.02 months, p=0.002). The median OS was not reached in high PD-L1 group, while it was 13.47 months in low PD-L1 group (P<0.01).

      Conclusion

      Tumor-educated platelets derived PD-L1 mRNA could be a surrogate biomarker predicting the PFS and OS of immunotherapy in patients with advanced non-small cell lung cancer.

  • +

    P2.09 - Pathology (ID 174)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Pathology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.09-08 - Correlation Between Hormone Receptor Expression and EGFR Gene Mutation in Lung Cancer Patients with Simultaneous Primary Breast Cancer (ID 2968)

      10:15 - 18:15  |  Author(s): Zhihuang Hu

      • Abstract

      Background

      Double primary breast cancer (BC) and lung cancer (LC) is not uncommon but research is limited. To decipher the inner pathogenesis, relationship between hormone receptor (HR) protein expression and EGFR gene mutation was explored in the present study.

      Method

      Clinicopathological characteristics of 400 female patients with double primary BC and LC were analyzed, while another 114 patients with single LC were compared correspondingly. Tissue samples were obtained from enrolled subjects to detect EGFR mutation status by gene sequencing analysis, and estrogen receptor (ER) and progesterone receptor (PR) expression was determined by immunohistochemistry.

      Result

      Among 169 patients, synchronous and metachronous double primary BC-LC cases accounted for 39.1% and 61.0%, respectively. For most female LC patients with simultaneous primary BC, adenocarcinoma was the dominant subtype (95.1%). The positivity rates were 13% for ER and 13% for PR in lung tumor tissues of 200 double BC-LC patients, slightly higher than those in single LC patients. Among BC-LC patients with mutant EGFR, 48.2% were either ER-positive (30.6%) or PR-positive (30.6%). But for those without EGFR mutation, both ER and PR could not be detected in lung tumor tissue samples. χ2 testfurther confirmed a significantly positive correlation between ER, PR expression and EGFR mutation in lung tumor tissues in double primary patients (P < 0.05). However, such relationship could not be similarly observed in single LC cases. Besides, the presence of family tumor history was associated with the onset time of the two primary cancers.

      Conclusion

      Double primary BC-LC patients have distinctive clinicopathological features. Expression of HRs (both ER and PR) significantly correlated with EGFR mutation status in their lung tumor tissues.